Pharmacokinetics of Enfuvirtide in a Patient with Impaired Renal Function
Open Access
- 1 December 2004
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (11) , e119-e121
- https://doi.org/10.1086/425917
Abstract
Enfuvirtide is the first member of the fourth class of antiretroviral drugs to become available. We present a case report of a human immunodeficiency virus (HIV)-positive patient with mild renal impairment who developed severe renal impairment secondary to tenofovir therapy while receiving enfuvirtide. Because the patient's pharmacokinetic profile was not significantly altered, compared with that of HIV-infected patients with normal renal function, no dose modifications were required.Keywords
This publication has 8 references indexed in Scilit:
- Tenofovir-Related Fanconi Syndrome with Nephrogenic Diabetes Insipidus in a Patient with Acquired Immunodeficiency Syndrome: The Role of Lopinavir-Ritonavir-DidanosineClinical Infectious Diseases, 2003
- Drug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of NephrotoxicityThe Lancet Healthy Longevity, 2003
- Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and AustraliaNew England Journal of Medicine, 2003
- Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South AmericaNew England Journal of Medicine, 2003
- Tenofovir‐Related Nephrotoxicity in Human Immunodeficiency Virus–Infected Patients: Three Cases of Renal Failure, Fanconi Syndrome, and Nephrogenic Diabetes InsipidusClinical Infectious Diseases, 2003
- Rapid Communication: Acute Renal Failure Associated with Tenofovir: Evidence of Drug-Induced NephrotoxicityThe Lancet Healthy Longevity, 2002
- Fanconi syndrome and renal failure induced by tenofovir: A first case reportAmerican Journal of Kidney Diseases, 2002
- Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patientswith human immunodeficiency virus: Inverse Gaussian density absorption and 2‐compartment disposition*Clinical Pharmacology & Therapeutics, 2002